Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.
about
Extracellular signal-regulated kinase 5 and cyclic AMP response element binding protein are novel pathways inhibited by vandetanib (ZD6474) and doxorubicin in mesotheliomasA "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy.UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models.
P2860
Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Vandetanib mediates anti-leuke ...... ally with DNA damaging agents.
@ast
Vandetanib mediates anti-leuke ...... ally with DNA damaging agents.
@en
type
label
Vandetanib mediates anti-leuke ...... ally with DNA damaging agents.
@ast
Vandetanib mediates anti-leuke ...... ally with DNA damaging agents.
@en
prefLabel
Vandetanib mediates anti-leuke ...... ally with DNA damaging agents.
@ast
Vandetanib mediates anti-leuke ...... ally with DNA damaging agents.
@en
P2093
P2860
P1476
Vandetanib mediates anti-leuke ...... ally with DNA damaging agents.
@en
P2093
Deborah DeRyckere
Margaret E Macy
P2860
P2888
P304
P356
10.1007/S10637-010-9572-6
P577
2010-11-03T00:00:00Z